CTLA4 and melanoma: In addition, a transcriptome study analyzing advanced melanoma patients treated with nivolumab (anti-PD-1) alone or combined with ipilimumab (anti-CTLA-4) showed high T cell infiltration and IFNγ signalling signatures in patients clinically responding to the therapy.